Novo Nordisk A/S
LSE:0QIU

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
LSE:0QIU
Watchlist
Price: 374.075 DKK -0.26% Market Closed
Market Cap: kr8.8B

Relative Value

The Relative Value of one 0QIU stock under the Base Case scenario is hidden DKK. Compared to the current market price of 374.075 DKK, Novo Nordisk A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

0QIU Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

0QIU Competitors Multiples
Novo Nordisk A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
LSE:0QIU
1.6T DKK 5.2 15.7 10.9 12.7
US
Eli Lilly and Co
NYSE:LLY
997.4B USD 16.8 54.1 36.3 38.9
US
Johnson & Johnson
NYSE:JNJ
551.5B USD 5.9 20.6 14.4 17.6
CH
Roche Holding AG
SIX:ROG
281B CHF 4.6 29.7 12.6 14.7
UK
AstraZeneca PLC
LSE:AZN
217.8B GBP 5.1 31.4 20.4 29.8
CH
Novartis AG
SIX:NOVN
224.3B CHF 5.1 19.8 15.8 20.4
US
Merck & Co Inc
NYSE:MRK
280.3B USD 4.4 14.7 10.4 12.3
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
150.6B USD 2.4 15.3 7.7 10.6
FR
Sanofi SA
PAR:SAN
97.3B EUR 1.7 8.2 7.7 7.7
US
Bristol-Myers Squibb Co
NYSE:BMY
113.3B USD 2.4 18.8 6.7 8.8
P/E Multiple
Earnings Growth PEG
DK
Novo Nordisk A/S
LSE:0QIU
Average P/E: 22.8
15.7
2%
7.9
US
Eli Lilly and Co
NYSE:LLY
54.1
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.6
6%
3.4
CH
Roche Holding AG
SIX:ROG
29.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
38%
0.8
CH
Novartis AG
SIX:NOVN
19.8
17%
1.2
US
Merck & Co Inc
NYSE:MRK
14.7
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.3
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
US
Bristol-Myers Squibb Co
NYSE:BMY
18.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
LSE:0QIU
Average EV/EBITDA: 44.4
10.9
1%
10.9
US
Eli Lilly and Co
NYSE:LLY
36.3
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.4
2%
7.2
CH
Roche Holding AG
SIX:ROG
12.6
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
20.4
10%
2
CH
Novartis AG
SIX:NOVN
15.8
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.4
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
US
Bristol-Myers Squibb Co
NYSE:BMY
6.7
-9%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
LSE:0QIU
Average EV/EBIT: 94.4
12.7
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
38.9
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
17.6
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.7
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
29.8
23%
1.3
CH
Novartis AG
SIX:NOVN
20.4
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12.3
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
10%
0.9